Terms: = Thyroid cancer AND CALCB, Calcitonin AND Treatment
596 results:
1. Extent of Surgery for Medullary thyroid cancer and Prevalence of Occult Contralateral Foci.
Mao YV; Hughes EG; Steinmetz D; Troob S; Kim J; Tseng CH; Fishbein GA; Sajed DP; Livhits MJ; Yeh MW; Lee D; Angell TE; Wu JX
JAMA Otolaryngol Head Neck Surg; 2024 Mar; 150(3):209-214. PubMed ID: 38270925
[TBL] [Abstract] [Full Text] [Related]
2. [Precision medicine in endocrinology exemplified by medullary thyroid cancer].
Brandenburg T; Machlah YM; Führer D
Inn Med (Heidelb); 2024 Mar; 65(3):202-210. PubMed ID: 38231404
[TBL] [Abstract] [Full Text] [Related]
3. [Individualization of treatment in sporadic and hereditary medullary thyroid cancer].
Lorenz K; Machens A; Dralle H
Chirurgie (Heidelb); 2024 Mar; 95(3):186-191. PubMed ID: 38214736
[TBL] [Abstract] [Full Text] [Related]
4. Risk factors for cervical lymph node metastasis in the central or lateral cervical region in medullary thyroid carcinoma: a systematic review and meta-analysis.
Lin X; Huo J; Su H; Zhu C; Xu Y; Zhang F
Eur Arch Otorhinolaryngol; 2024 Feb; 281(2):547-561. PubMed ID: 37801162
[TBL] [Abstract] [Full Text] [Related]
5. Exploring the application value of pro-gastrin-releasing peptide in the clinical diagnosis and surgical treatment of medullary thyroid carcinoma.
Miao Q; Lv X; Luo L; Zhang J; Cai B
Cancer Med; 2023 Oct; 12(19):19576-19582. PubMed ID: 37754747
[TBL] [Abstract] [Full Text] [Related]
6. [calcitonin measurement in fine-needle washout fluids in detecting medullary thyroid cancer].
Zuraeva ZT; Nikankina LV; Kolesnikova GS; Abdulhabirova FM; Beltsevich DG; Malysheva NM; Mikheenkov AA
Probl Endokrinol (Mosk); 2023 Jun; 69(3):9-15. PubMed ID: 37448242
[TBL] [Abstract] [Full Text] [Related]
7. CD276 as a Candidate Target for Immunotherapy in Medullary thyroid cancer.
Hińcza-Nowak K; Kowalik A; Walczyk A; Pałyga I; Gąsior-Perczak D; Płusa A; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373167
[TBL] [Abstract] [Full Text] [Related]
8. Validation of miRNAs as diagnostic and prognostic biomarkers, and possible therapeutic targets in medullary thyroid cancers.
Mondin A; Bertazza L; Barollo S; Pedron MC; Manso J; Piva I; Basso D; Merante Boschin I; Iacobone M; Pezzani R; Mian C; Censi S
Front Endocrinol (Lausanne); 2023; 14():1151583. PubMed ID: 37361540
[TBL] [Abstract] [Full Text] [Related]
9. Radioactive iodine in the management of medullary carcinoma of the thyroid.
Rowell NP
Br J Radiol; 2023 Aug; 96(1148):20220660. PubMed ID: 37335288
[TBL] [Abstract] [Full Text] [Related]
10. Medullary thyroid cancer: Updates and Challenges.
Gild ML; Clifton-Bligh RJ; Wirth LJ; Robinson BG
Endocr Rev; 2023 Sep; 44(5):934-946. PubMed ID: 37204852
[TBL] [Abstract] [Full Text] [Related]
11. Natural History and Predictive Factors of Outcome in Medullary thyroid Microcarcinoma.
Kesby N; Mechera R; Fuchs T; Papachristos A; Gild M; Tsang V; Clifton-Bligh R; Robinson B; Sywak M; Sidhu S; Chou A; Gill AJ; Glover A
J Clin Endocrinol Metab; 2023 Sep; 108(10):2626-2634. PubMed ID: 36964913
[TBL] [Abstract] [Full Text] [Related]
12. Clinical Evolution of Sporadic Medullary thyroid Carcinoma With Biochemical Incomplete Response After Initial treatment.
Prete A; Gambale C; Torregrossa L; Ciampi R; Romei C; Ramone T; Agate L; Bottici V; Cappagli V; Molinaro E; Materazzi G; Elisei R; Matrone A
J Clin Endocrinol Metab; 2023 Jul; 108(8):e613-e622. PubMed ID: 36722192
[TBL] [Abstract] [Full Text] [Related]
13. Update on Management of Medullary thyroid Carcinoma: Focus on Nuclear Medicine.
Treglia G; Rufini V; Piccardo A; Imperiale A
Semin Nucl Med; 2023 Jul; 53(4):481-489. PubMed ID: 36702731
[TBL] [Abstract] [Full Text] [Related]
14. Other markers of medullary thyroid cancer, not only calcitonin.
Censi S; Manso J; Mian C
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651167
[TBL] [Abstract] [Full Text] [Related]
15. Early postoperative calcitonin-to-preoperative calcitonin ratio as a predictive marker for structural recurrence in sporadic medullary thyroid cancer: A retrospective study.
Jiao Z; Wu T; Jiang M; Jiang S; Jiang K; Peng J; Luo G; Yu Y; Chen W; Yang A
Front Endocrinol (Lausanne); 2022; 13():1094242. PubMed ID: 36589824
[TBL] [Abstract] [Full Text] [Related]
16. [Risk factors of recurrence or metastasis in patients with medullary thyroid carcinoma].
Guo FL; Li LJ; Ruan XH; Fu GM; Zhao JZ; Hou XK; Gao M; Zheng XQ
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(48):3849-3855. PubMed ID: 36540922
[No Abstract] [Full Text] [Related]
17. Oncologic outcomes of calcitonin-negative medullary thyroid carcinoma.
Yue W; Zhang Y
Front Endocrinol (Lausanne); 2022; 13():1025629. PubMed ID: 36506082
[TBL] [Abstract] [Full Text] [Related]
18. Parathyroid adenoma presenting as chronic pancreatitis: A case report and literature review.
Fu CH; Chen HF
Medicine (Baltimore); 2022 Nov; 101(46):e31750. PubMed ID: 36401406
[TBL] [Abstract] [Full Text] [Related]
19. Lobectomy may be more appropriate for patients with early-stage medullary thyroid cancer older than 60 years old.
Yang B; Niu G; Li X; Ma F; Ma Y; Hu S
Front Endocrinol (Lausanne); 2022; 13():1015319. PubMed ID: 36339396
[TBL] [Abstract] [Full Text] [Related]
20. [The trends in early precision diagnosis and treatment strategies of multiple endocrine neoplasia type 2].
Qi XP; Jin B
Zhonghua Wai Ke Za Zhi; 2022 Nov; 60(11):973-980. PubMed ID: 36323578
[TBL] [Abstract] [Full Text] [Related]
[Next]
